Navigation Links
Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
Date:12/13/2012

Palo Alto-based Lyncean Technologies, Inc., today announced its first sale of a Compact Light Source, a miniature synchrotron X-ray source employing state-of-the-art laser-beam and electron-beam technology.

A Lyncean "Compact Light Source" (CLS) was purchased by researchers from the newly-formed Center for Advanced Laser Applications (CALA) in Germany, a joint project of the Ludwig Maximilians University of Munich (LMU) and the Technical University Munich (TUM). The device will be fully built and tested in Lyncean's facility in Palo Alto, Calif. and delivered to Munich in early 2014.

"Today is a milestone for us," said Ronald Ruth, Lyncean's founder and Chairman of the Board. "We feel we have an innovative tool, especially as X-rays are playing a growing role in areas like structural biology, medical science, nanotech and fuel cell research. We've been fortunate to have had so much support developing the technology, but putting a CLS in the hands of scientists has always been the ultimate goal."

With its first sale to a team of researchers, Lyncean expects a growing demand by scientists and students at the forefront of biomedical X-ray imaging research. Prof. Franz Pfeiffer, Chair for Biomedical Physics at TUM, leads a group of X-ray scientists pioneering new imaging techniques that reveal striking details in soft tissue that have been difficult to detect using conventional methods. He's eager to see the new X-ray source put to use.

"The field of X-ray imaging is evolving rapidly, and with this novel source, we are adding a powerful tool to our facility," Dr. Pfeiffer said. "I expect having our own CLS here in Munich will significantly boost the research projects in our excellence cluster Munich-Centre for Advanced Photonics (MAP)."

Lyncean has been collaborating with Dr. Pfeiffer's group informally since 2007, when an impromptu visit one afternoon led to an experiment and later publication that was featured on the cover of the Journal of Synchrotron Radiation in January 2009, [doi:10.1107/S090904950803464X]. Subsequent experiments using the CLS prototype operating at Lyncean have produced a variety of joint publications, primarily with a medical emphasis, highlighting the machine's ability to improve tumor detection and early diagnosis of lung disease (a study that was just published in the Proceedings of the National Academy of Sciences [doi: 10.1073/pnas.1206684109]).

"Because the CLS is a new breed of X-ray source, with unique properties, we work with X-ray scientists to understand their applications," Dr. Ruth said. "The TUM collaboration is a good example of how we can successfully adapt our source for a particular application, in this case biomedical imaging."

The US National Institutes of Health provided funding for CLS development in order to help address the growing demand of life-science users who rely on synchrotrons for structural biology research. In addition to the CLS, Lyncean has also developed X-ray applications such as protein crystallography and power diffraction using focused beams from special X-ray optics. Researchers, though, use a wide variety of experimental techniques when applying synchrotron radiation to their own problems. The CLS, like a large synchrotron facility, is designed to perform a breadth of X-ray applications spanning fields from biology and chemistry to nanotechnology and materials science.


'/>"/>

Contact: Rod Loewen
rod_loewen@lynceantech.com
650-320-8300 x405
Lyncean Technologies, Inc.
Source:Eurekalert  

Related biology news :

1. NREL researchers use imaging technologies to solve puzzle of plant architecture
2. New energy technologies promise brighter future
3. Cross Match Technologies Undoubtedly Offers the Highest Value to Customers in the North American Biometrics Market, Says Frost & Sullivan
4. Life Technologies to supply new Covaris DNA fragmenting products for Ion Torrent Semiconductor Sequencers
5. ONR lines up speakers and technologies for 2012 Naval Conference
6. New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs
7. ASU awarded $3 million to research solar energy technologies, launch energy Ph.D. program
8. DNA Sequencing: Emerging Technologies and Applications
9. NHS set to benefit from UK-led technologies
10. New technologies for a blue future
11. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: